STOCK TITAN
  1. Home
  2. News
  3. LRMR

Larimar Therapeutics to Participate in SVB Leerink CybeRx Series: Neuromuscular, Rare Diseases & Genetic Medicines Event

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences

BALA CYNWYD, Pa., Sept. 16, 2021 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that company management will participate in 1x1 investor meetings at the SVB Leerink CybeRx Series: Neuromuscular, Rare Diseases & Genetic Medicines 1x1 Event. The event is taking place virtually September 22-23, 2021.

About Larimar Therapeutics

Larimar Therapeutics, Inc. (Nasdaq: LRMR), is a clinical-stage biotechnology company focused on developing treatments for complex rare diseases. Larimar’s lead compound, CTI-1601, is currently being evaluated in a Phase 1 clinical program in the U.S. as a potential treatment for Friedreich's ataxia. Larimar also plans to use its intracellular delivery platform to design other fusion proteins to target additional rare diseases characterized by deficiencies in intracellular bioactive compounds. For more information, please visit: https://larimartx.com.

Investor Contact:
Joyce Allaire
LifeSci Advisors
jallaire@lifesciadvisors.com
(212) 915-2569

Company Contact:
Michael Celano
Chief Financial Officer
mcelano@larimartx.com
(484) 414-2715


Stock LRMR logo
Larimar Therapeutics, Inc.

NASDAQ:LRMR

LRMR Rankings

#3018 Ranked by Market Cap
#3294 Ranked by Stock Gains
N/A Ranked by Dividends

LRMR Latest News

Mar 14, 2024
Larimar Therapeutics Reports Fourth Quarter and Full Year 2023 Operating and Financial Results and Provides Update on Nomlabofusp Development
Mar 11, 2024
Larimar Therapeutics Announces the Dosing of the First Patient in Long-term Open Label Extension Study for Nomlabofusp in Patients with Friedreich’s Ataxia
Mar 6, 2024
Larimar Therapeutics to Present at the Leerink Partners Global Biopharma Conference
Feb 16, 2024
Larimar Therapeutics Announces Closing of Underwritten Public Offering of Common Stock and Exercise in Full of the Underwriters’ Option to Purchase Additional Shares
Feb 14, 2024
Larimar Therapeutics Announces Pricing of Underwritten Public Offering of Common Stock

LRMR Stock Data

485.52M
32.55M
1.34%
83.55%
5%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States of America
BALA CYNWYD

About LRMR

larimar therapeutics, inc. (nasdaq:lrmr), is a clinical-stage biotechnology company focused on developing treatments for complex rare diseases. the company’s lead compound, cti-1601, is currently being evaluated in a phase 1 clinical program as a potential treatment for friedreich’s ataxia, a rare and progressive genetic disease. larimar also plans to use its intracellular delivery platform to design other fusion proteins to target additional rare diseases characterized by deficiencies in intracellular bioactive compounds. for more information, please visit: https://larimartx.com.